## Abstract Three cases of osteonecrosis in patients receiving prednisone as part of multidrug chemotherapy for lymphoma are presented. These patients are discussed in the context of previously reported series. The etiology of steroidβinduced osteonecrosis and its radiologic manifestations are revi
Cyclical combination chemotherapy and thyroid function in patients with advanced hodgkin's disease
β Scribed by Sutcliffe, S. B. ;Chapman, Ramona ;Wrigley, P. F. M.
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 555 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Clinical and biochemical assessment of thyroid function was undertaken in patients with Hodgkin's disease at designated points following diagnosis. At diagnosis, two of 20 patients had either abnormally low routine thyroid indices, or elevated thyroid stimulating hormone (TSH) levels that were not due to iodineβbased investigations. Following lymphography, 76.5% of patients had TSH levels that remained elevated for a median period of 3 months. No detectable thyroid dysfunction was induced during chemotherapy. Fiftyβfour patients were studied at a median time of 35 months after chemotherapy. One euthyroid patient had a nodular goitre, and one had abnormal thyroid indices. TSH levels were elevated in 44% of patients, although the median TSH level for the group was normal. Half the patients had abnormal TRH stimulation tests. Sixty patients were studied after irradiation and chemotherapy. Four patients had clinical thyroid dysfunction, and 10% of routine thyroid indices were abnormal. TSH levels were abnormal in 80%, with a markedly elevated median level. All thyroid releasing hormone stimulation tests were abnormal.
π SIMILAR VOLUMES
## Abstract Seventeen patients with advanced, previously treated Hodgkin's disease received therapy with a combination of streptozotocin 500 mg/m^2^ /day i.v. days 1β5, CCNU 100 mg/m^2^ orally day 1, adriamycin 45 mg/m^2^ i.v. day 1, and bleomycin 15 mg/m^2^ i.m. days 1 and 8 at 28βday intervals (S